France Pharma RepTrak 2017

Similar documents
Pharma RepTrak The World s Most Reputable Pharmaceu<cal Companies. May 2016

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION)

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES

Corporate Reputation of Pharma in 2017 the Patient Perspective

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION)

2017 Germany RepTrak. 22 nd March 2017 Nicolas Georges Trad, Executive Partner Nick Adams, VP & Strategic Consulting Director

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION)

March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella

The Results of the 2012 RepTrak Study What the Reputation Economy means for South Africa 2012

RepTrak. Measuring and managing the reputation of some of the largest and best performing companies around the world

Strategic vision of Pharma Market

Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation

2010 Global Reputation Pulse Study The Most Reputable Companies in the World

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION)

Reputation of UK Companies in Decline for the First Time Since 2008 Financial Crash, Reveals UK s Biggest Annual Reputation Ranking

Pharmaceutical Companies and Social Media: Developing New Strategies

The Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer Experiences Physicians Want Author: John Mack

South Africa RepTrak Pulse. Annual RepTrak Report

Competing for Image Leadership

70.1 WHAT IS TAKING A BITE OUT OF APPLE S REPUTATION?

Evaluate Data Kit Pharma, Biotech and Medtech, May 2018

Fairtrade Labelling Organizations International Label Perceptions Survey Findings Report ITALY

South Africa. National Pulse 2017 Report

Public Sector Reputation Index: The Civil Aviation Authority s Reputation Index results benchmarked against the wider public sector

LSE Health Market Access Academy April 2018, London September 2018, London

Theme Sub-theme Quote / issue. Inconsistency and

RepTrak Belgium 2012 LET S SET THE TONE! RepTrak 2012 Belgium 1

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

THE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES

Code of Conduct Interfarma Review 2012

THE STATE OF CUSTOMER EXPERIENCE IN EUROPEAN PHARMA, 2017: PHYSICIAN INTERACTIONS

The Advancing Women Organizational Assessment Feedback Results. WILOA Test Aggregate. May 2017

THE TOP 5 TRENDS IN HCP S DIGITAL PREFERENCE. PHARMAFUTURE. All rights reserved.

GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS

IMPROVING TALENT ACQUISITON OUTCOMES

by Dennis van Rooij and Tim van Tongeren

AN EXTERNAL VIEW OF TRUST: EDELMAN SESSION JULY For more information please contact

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

EMPLOYEE ENGAGEMENT SURVEY

NEXT Annual Report 2017

Important notice. 139 th Ordinary general meeting of shareholders. Christophe Weber President & Chief Executive Officer

The Fourth Edelman Survey on Trust & Credibility

Employee Well-Being and Satisfaction Survey Results 2015

Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients

The 2014 Enterprise Value Study: How Confidence Drives Stakeholder Behaviors. October 2014

Assessing Public Support for Regulation for Fairer Trading Practices. June 2016 Report

Social Responsibility. Executive Briefing. The Millennium Poll on Corporate. Results of the. largest survey ever of. global public opinion

Sponsorship & Branding opportunities

Consumer attitudes and perceptions on sustainability

EMPLOYEE ENGAGEMENT SURVEY

Analysis of Lebanon s Pharmaceutical Market

The Business End of High Performing E-S-G Companies. USF Patel College of Global Sustainability September 5, 2018

Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking

Gender Pay Gap Report 2018

May Marketing ROI INSIDE. Facing pharma s big challenges. A call for innovation. Creating brand advocates. in partnership with

2016 Clinical Trials Roundup: The Next Generation

Best-in-Class Pharma Strategy. Crafting. Data. Concepts. Methods. Tools. Smart Pharma Consulting Expertise. March Smart Pharma Consulting

The Patient-Reported Outcome (PRO) Consortium:

Management Excellence in Christian Organizations: An Employee Perspective Key Insights on Managing Christian Organizations

EMPLOYEE ENGAGEMENT SURVEY

Corporate Social Responsibility

Beyond Philosophy LLC. Michael FEBRUARY 2016 BEYONDPHILOSOPHY.COM

EMPLOYEE ENGAGEMENT SURVEY

Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V

Global and China Biopharmaceutical Industry Report, 2010

UAF Administrative Services Work Environment Survey. Prepared for: University of Alaska, Fairbanks Administrative Services

in partnership with EMPLOYEE OUTLOOK EMPLOYEE VIEWS ON WORKING LIFE

Representing Healthcare Distribution in Canada

The power of provenance

Climate Change Polling Results

State of Sustainable Business Survey 2014

PHARMA IN FOCUS WHITE PAPER: JOB SATISFACTION IN THE AUSTRALIAN PHARMACEUTICAL INDUSTRY April 2016

Global Workforce Study. Australia - At a Glance

GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS

USP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure

Survey Results Participation in the Sharing Economy

Financial literacy among Canadian entrepreneurs and business owners

2017 Clinical Trials Roundup: The Evolution Continues

Could trust cost you a generation of talent? Global generations 3.0: A global study on trust in the workplace

Product Overview: Global Life Sciences Survey. One Firm. Complete Solutions.

Generic Series: Optimizing Brand Lifecycle Management

2016 Socrata Open Data Benchmark Study. Executive Summary

Slavery Alert: Consumer Poll, United States 1

Welcome to the CMC Strategy Forum Europe 2016

SPRING 2012 EMPLOYEE OUTLOOK PART OF THE CIPD OUTLOOK SERIES

Organic Market Research Study

THE DIGITAL. Top trends SAVVY HCP

Pharmaceutical lobbying

GENDER PAY GAP REPORT

NZ Police 2007 Employee Engagement Survey (Organisational Health Audit) Results Presentation

the company behind the brand: in reputation we trust

Perceptions of Privacy Online and in the Digitally Connected World Data Privacy Research Results Summary Released January 28, 2015

Football Sponsorship: Maximising sponsors Benefits. Mary Charalambous-Papamiltiades European University Cyprus

HOW CAN DIGITAL POLICE SOLUTIONS BETTER SERVE CITIZENS EXPECTATIONS?

Thema: Maatschappelijke verantwoordelijkheid van de farmaceutische industrie: beschikbaarheid en betaalbaarheid van de toegang tot zorg

EMPLOYEE ENGAGEMENT SURVEY

A Physician s consideration towards Biosimilars. João Eurico Fonseca

I. Understanding the Drivers of Tax Staff Retention and Engagement

Transcription:

France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1

Why Measure Reputation? The success of your company depends on getting people to support you. Reputation is an emotional bond that ensures Customers buy your products The general public recommend your company Policy makers and regulators give you a license to operate The financial community invest in you The media report favorably on your point of view Employees deliver on your strategy RepTrak is a registered trademark of Reputation Institute. Copyright 2017 Reputation Institute. All rights reserved. 2

The RepTrak Model Summary The RepTrak System measures a company s ability to deliver on stakeholder expectations on the 7 key rational dimensions of reputation A company that delivers on expectations in the 7 domains will earn support from its stakeholders PRODUCTS & SERVICES INNOVATION WORKPLACE GOVERNANCE CITIZENSHIP LEADERSHIP PERFORMANCE PURCHASE RECOMMEND CRISIS PROOF VERBAL SUPPORT INVEST WORK REPUTATION DIMENSIONS REPUTATION (RepTrak Pulse) SUPPORTIVE BEHAVIORS RepTrak is a registered trademark of Reputation Institute. Copyright 2017 Reputation Institute. All rights reserved. 3

Reputation Drives Support (France drivers) - Only Companies in the Excellent RepTrak Pulse Range Achieve Support Above 50% Poor 0-39 4% 9% 21% 42% 75% 2% 6% 14% 32% 69% 1% 8% 22% 50% 78% 4% 9% 17% 36% 68% 2% 4% 11% 22% 58% 4% 7% 17% 30% 59% 3% 6% 13% 26% 57% Source: 2017 France RepTrak 4

Reputation Management Requires Clear Measurement and Structure What You Do Reputation Behavior Business Results Products Investments Customer Service Employment What You Say Branding Marketing Public Relations Sponsorship What Others Say Media Topic Experts Key Opinion Leaders Friends/Family 5

Reputation Institute Pharma RepTrak 2017 2017 Pharma RepTrak Global 6

Welcome to the Pharma RepTrak 2017 The 2017 Global Pharma RepTrak measures 17 companies with the general public in 8 countries. With nearly 17,000 ratings collected in Q1 and Q2, 2017 this is the largest study of corporate reputation in the world Respondents are qualified at 2 tiers: Familiarity: Respondent must be somewhat or very familiar with companies RepTrak Pulse: 75% completion of pulse rating to be included The results tell us: Which pharmaceutical companies are best regarded by the general public What drives trust and support with general public How the top companies are living up to public expectations BRAZIL CANADA FRANCE GERMANY ITALY SPAIN THE UNITED KINGDOM THE UNITED STATES RepTrak is a registered trademark of Reputation Institute. Copyright 2017 Reputation Institute. All rights reserved. 7

Pharma Reputation Development 2014 2017 Pharma continues positive trend into 2017 and has for the first time a strong Reputation 80 75 70 65 65.8 66.2 68.2 71.8 Countries measured 2014-2017 60 55 Normative Scale 50 2014 2015 2016 2017 Source: 2017 Pharma RepTrak n = 16,898 ratings from general public across 8 countries Global RepTrak Pulse scores that differ by more than +/- 0.2 are significantly different at the 95% confidence level Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 8

Reputation of the Pharma Industry by Market Mostly strong Reputation across markets, with best Reputation in the US and poorest in France 6.9 71.2 72.6 72.5 2.4 Global Pharma RepTrak Score Canada 4.8 UK 3.6 69.5 France Germany 71.8 USA 70.8 5.8 Spain Italy 7.2 73.5 72.0 Brazil Indicates statistically significant increase All RepTrak Pulse scores that differ by more than +/- 0.7 are significantly different at the 95% confidence level 72.4 1.5 Normative Scale Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 9

The youngest generation are the most critical towards the Industry Overall General Population Male 71.8 Female 70.9 72.8 Gender 18-24 45-64 25-34 35-44 Age 70.1 71.8 72.0 72.7 Low High Middle 69.8 71.2 72.2 Education Low Middle High 69.4 72.1 73.7 Income France Spain Canada Italy 69.5 70.8 71.2 72.0 Country All RepTrak Pulse scores that differ by more than +/- 0.4 are significantly different at the 95% confidence level Brazil 72.4 Germany 72.5 UK 72.6 USA 73.5 Normative Scale Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 10

Best Reputation in Pharma AbbVie leads, and except for GSK and Pfizer all Pharma companies have a strong reputation Tier 1 Tier 2 Tier 3 Tier 4 Company All RepTrak Pulse scores that differ by more than +/- 1.0 are significantly different at the 95% confidence level 2017 RepTrak Pulse AbbVie 74.5 Novo Nordisk 74.0 Takeda Pharmaceutical 73.8 Roche 73.4 Janssen Pharmaceuticals 72.5 Gilead Sciences 72.4 Bayer 72.3 MSD (Merck Sharp & Dohme) 72.2 Sanofi 72.0 Eli Lilly 71.9 Allergan 71.8 Merck KGaA 71.6 Bristol-Myers Squibb 70.5 AstraZeneca 70.4 Novartis 70.4 GlaxoSmithKline 68.5 Pfizer 68.4 Development since 2016 5.3 3.8 New company 3.7 New company 1.7 4.0 4.1 3.4 1.8 4.1 3.1 3.4 2.0 3.5 Normative Scale Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 11

Reputation Institute Pharma RepTrak 2017 2017 Pharma RepTrak France 12

Welcome to the Pharma RepTrak 2017 France The 2017 France Pharma RepTrak measures 24 companies with the general public in France through 2849 ratings. Respondents are qualified at 2 tiers: Familiarity: Respondent must be somewhat or very familiar with companies RepTrak Pulse: 75% completion of pulse rating to be included The results tell us: Which pharmaceutical companies are best regarded by the general public in France What drives trust and support with general public How the top companies are living up to public expectations RepTrak is a registered trademark of Reputation Institute. Copyright 2017 Reputation Institute. All rights reserved. 13

Who is the General Public? Gender Age Education Somewhat or very familiar with the pharma companies 52% 48% 44% 13% 21% 43% 3% 55% 23% Male Female 18-24 25-34 35-44 45-64 Low Middle High Balanced female-male ratio 67% are 35 or older 43% with high education RepTrak is a registered trademark of Reputation Institute. Copyright 2017 Reputation Institute. All rights reserved. 14

Pharma Companies Will Benefit from Telling Their Company Story - Enterprise Drives 62% of Willingness to Support 62% 38% > ENTERPRISE PRODUCT SUPPORTIVE BEHAVIORS RECOMMEND COMPANY SAY SOMETHING POSITIVE GIVE THE BENEFIT OF DOUBT BUY PRODUCTS INVEST WORK FOR COMPANY 15

Pharma Reputation Development 2013 2017 in France: Pharma Reputation Improves in 2017 80 75 70 69,5 65 60 60,6 63,4 64,5 65,8 55 Normative Scale 50 2013 2014 2015 2016 2017 Source: 2017 Pharma RepTrak in France N = 2,078 ratings from general public across France RepTrak Pulse scores that differ by more than +/- 3.1 are significantly different at the 95% confidence level Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 16

Pharma has a high average to strong perception across the 7 dimensions. 2017 Pharma in France Across the 7 dimensions Pharma Companies has the strongest perception for Financial Performance. 72,6 74,6 66.0 69,5 72,7 72,6 The weakest and average perceptions are for the three CSR dimensions: Workplace, Citizenship and Governance. 66,3 66,3 France RepTrak Industry Pulse scores that differ by more than +/- 6,1 and dimension scores that differ by more than +/- 2.0 are significantly different at the 95% confidence level 68,5 Normative Scale Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 17

Pharma has a high average to strong perception across the 7 dimensions. 11,5% 2017 Industry Weights 16,8% 9,9% 66.0 18,8% 16,7% 12,4% 14,0% 2017 Pharma in France 72,6 66,3 74,6 66.0 69,5 66,3 72,7 68,5 72,6 Across the 7 dimensions Performance is perceived as the least important. In order to be effective, French Pharma companies should focus mostly on the three CSR dimensions, which unfortunately in 2017 are perceived with an average reputation. Normative Scale France RepTrak Industry Pulse scores that differ by more than +/- 6,1 and dimension scores that differ by more than +/- 2.0 are significantly different at the 95% confidence level Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 18

Why is CSR important for Pharma companies in France? 2017 9,9% 16,7% Top 3 priorities for Reputation 11,5% 16,8% 12,4% 14,0% 1. Governance 2. Citizenship 3. Product & Services 18,8% CSR Index 49,6% 19

Reputation Institute Pharma RepTrak 2017 The Best Reputation in Pharma - France 20

2017 The 5 Pharma Companies with the Best Reputations in France Company 2017 RepTrak Pulse 75,8 75,5 75,0 75,0 Normative Scale Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 All RepTrak Pulse scores that differ by more than +/- 3,1 are significantly different at the 95% confidence level 74,3 21

2017 Pharma France RepTrak # Company 2017 RepTrak Pulse # Company 2017 RepTrak Pulse 1 Allergan 75,8 9.1 13 Bristol-Myers Squibb 70,9 6.1 2 ViiV 75,5 3 Takeda Pharmaceutical 75,0 14 AstraZeneca 69,7 15 Eli Lilly 69,5 3.4 3.6 4 Sartorius Stedim Biotech 75,0 5 MSD 74,3 6 Amgen 74,2 7 Celgene 73,5 8 Gilead Sciences 73,2 9 Roche 73,1-5.5 16 Biomerieux 69,4 17 IPSEN 66,6 18 GlaxoSmithKline 66,0 19 Merck KGaA 64,4 20 Novartis 63,9 21 Pfizer 63,7 1 6.1 2.1 6 10 AbbVie 73,0 11 Janssen Pharmaceuticals 73,0 12 Novo Nordisk 71,8 9.9 2.5-22 Sanofi 62,7 23 Bayer 61,5 24 Servier 31,0 3 4 Normative Scale All RepTrak Pulse scores that differ by more than +/- 3,1 are significantly different at the 95% confidence level Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 22

Pharma Industry overview in France Products/services Innovation # Company 2017 Score # Company 2017 Score 1 Sartorius Stedim Biotech 77,8 1 Sartorius Stedim Biotech 77,1 2 MSD 77,4 2 MSD 75,8 3 Allergan 76,8 3 ViiV 75,8 Workplace Citizenship # Company 2017 Score 1 Sartorius Stedim Biotech 76,0 # Company 2017 Score 1 Sartorius Stedim Biotech 73,7 2 Allergan 74,8 2 Allergan 73,2 3 MSD 74,1 3 Amgen 72,8 Normative Scale All scores that differ by more than +/- 6,1 are significantly different at the 95% confidence level Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 23

Pharma Industry overview in France Governance # Company 2017 Score 1 Sartorius Stedim Biotech 74,2 2 MSD 73,5 3 ViiV 73,0 Leadership # Company 2017 Score 1 Sartorius Stedim Biotech 77,6 2 Allergan 76,6 3 MSD 76,5 Performance # Company 2017 Score 1 Sartorius Stedim Biotech 78,2 2 Novartis 78,0 3 Roche 77,8 All scores that differ by more than +/- 6,1 are significantly different at the 95% confidence level Normative Scale Excellent/ Top Tier 80+ Strong/ Robust 70-79 Avg./ Moderate 60-69 Weak/ Vulnerable 40-59 Poor/ Lowest Tier <40 24

Reputation Institute Pharma RepTrak 2017 Key dynamics in Pharma - France 25

Pharma in France is facing a large Risk or Opportunity: 52%-66% are Uncertain About What Pharma Companies do Across the 7 dimensions FENCE SITTERS = % of public who is neutral or not sure about the company s performance on that dimension PRODUCTS & SERVICES 3% 43% 53% 2% 55% INNOVATION 2% 43% 52% 3% 55% WORKPLACE 3% 31% 54% 12% 66% GOVERNANCE 5% 32% 55% 9% 64% CITIZENSHIP 6% 32% 56% 6% 62% LEADERSHIP 2% 39% 54% 6% 60% PERFORMANCE 2% 47% 47% 5% 52% DISAGREE STRONGLY AGREE NEUTRAL NOT SURE 26

Supportive Behaviours Industry Distribution FENCE SITTERS Buy 9% 41% 45% 5% 50% Trust To Do The Right Thing 9% 40% 45% 6% 51% Recommend Company 11% 39% 45% 5% 50% Say Positive 10% 38% 46% 6% 52% Work For 14% 37% 42% 7% 49% Invest 15% 37% 40% 8% 48% Benefit Of Doubt 11% 36% 46% 7% 53% Welcome To Neighbourhood 13% 35% 44% 8% 52% DISAGREE STRONGLY AGREE NEUTRAL NOT SURE 27

Industry Battery FENCE SITTERS = % of public who is neutral or not sure about the company s performance on that dimension Committed to advances in treatments and cures 4% 48% 42% 5% 47% Provides complete and reliable product information 6% 42% 45% 7% 52% Promotes wellness and healthy lifestyles 7% 40% 45% 8% 53% Has strong data privacy and security practices 4% 40% 43% 14% 57% Committed to patient and personal safety 5% 40% 42% 13% 55% Handles product recall proactively 4% 39% 43% 14% 57% Practices responsible product marketing and advertising 5% 37% 47% 12% 59% Sets prices fairly 7% 35% 49% 10% 59% DISAGREE STRONGLY AGREE NEUTRAL NOT SURE 28

Trust in a Crisis: If the company as was facing a crisis, I would give them the benefit of the doubt 6% 44% 47% 3% TOP 3 6% 45% 46% 3% 5% 50% 47% 3% BOTTOM 3 DISAGREE NEUTRAL STRONGLY AGREE NOT SURE 13% 48% 25% 15% 16% 50% 21% 13% 60% 25% 8% 7% DISAGREE NETURAL STRONGLY AGREE NOT SURE 29

French Pharma Companies Top 10 drivers 2017 Rank Attribute Weight Distribution FENCE SITTERS 1. Has a positive influence on society 5,9% 6 47% 39% 8% 55% 2. Supports good causes 5,7% 7% 43% 30% 20% 63% 3. Offers high quality products and services 5,5% 3% 44% 49% 4% 48% 4. 5. Offers products and services that are a good value for the money Is open and transparent about the way the company operates 5,5% 5,5% 5% 8% 50% 44% 38% 34% 7% 14% 57% 58% 6. Acts responsibly to protect the environment 5,4% 8% 42% 30% 19% 61% 7. Behaves ethically 5,3% 8% 45% 30% 17% 62% 8. Stands behind its products and services 5,0% 3% 42% 49% 6% 48% 9. Is fair in the way it does business 4,6% 4% 45% 33% 19% 64% 10. Rewards its employees fairly 4,5% 4% 38% 27% DISAGREE NEUTRAL STRONGLY AGREE NOT SURE 31% 69% *FENCE SITTERS = % of public who is neutral or not sure about the company s performance on that dimension 30

On a global level, Familiarity with the Industry is generally low among the public 100% 90% 80% 70% Global RepTrak 100 Pharma Companies Familiarity % 60% 50% 40% 30% 20% 10% 0% 50,0 55,0 60,0 65,0 70,0 75,0 80,0 85,0 RepTrak Pulse Score 31

Company Awareness is not enough... Improving Company Familiarity is required to win - A 20 point increase in reputation as Familiarity grows Awareness Familiarity Aware 41,6% 100% Excellent 17,0% Good 35,6% Reputation +20,3 73,0 66,3 n= 405 80,8 n= 405 Not Aware 58,4% Sufficient 24,0% Poor 23,4% 60,5 n= 405 Poor Sufficient Good Excellent Familiarity 32

French Pharma Scorecard Top 10 drivers 2017 High Quality Value for money Stands behind its products Environmentally Responsible Positive influence on society Supports good causes Rewards employees Fairly Fair in Business Behaves Ethically Open and Transparent 33

RepTrak Helps Measure and Manage Your Reputation Reputation helps you to drive your business What You Do Reputation Behavior Business Results Products Investments Customer Service Employment What You Say Branding Marketing Public Relations Sponsorship What Others Say Media Topic Experts Key Opinion Leaders Friends/Family 34

Next steps 1. How can we help you take action based on the results? 2. How can we help you share this with the leaders in the countries? Ask us at oforlini@reputationinstitute.com 35